ASMBR 2016

October 2016- Entera presents the "Novel Oral PTH (1-34) formulation with reduced pharmacokinetic variability" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Atlanta, Georgia. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented results from a clinical study utilizing the novel formulation technology in its Oral PTH 1-34) with with decreased inter-subject variability and an absorption profile close to that of the commercially available injectable PTH (1-34).

pdfSee poster